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1. Introduction 
Basal cell carcinoma (BCC), first described by Jacob in the early 1800(1), is the most common 
cancer in the general population, accounting for 80% of nonmelanoma skin cancer (2). 
Worldwide incidence is increasing by about 10% per annum, so the prevalence of BCC will 
soon equal that of all other cancers combined(3). The average lifetime risk for white skinned 
individuals to develop BCC is approximately 30 %(4). BCC is uncommon in dark skinned 
races. Studies have estimated that 1.2% to 4.6% of BCCs arise in black patients (5). BCC is 
more common in men than in women (ratio of approximately 2:1). BCC most commonly 
occurs in older than 50 years old (6). Interestingly, women younger than 40 years of age 
have been found to slightly outnumber men in this age group (7). The increased incidence 
rates could be attributed to changes in sunbathing behavior in the young and the 
middleaged, which has changed during the 20th century. Particularly after the Second 
World War, more people had leisure time for outdoor activities. Also, women’s clothing 
changed allowing larger parts of the body to be exposed to the sun (8). 
2. Etiology 
The etiology of BCC is still unclear but appears to be of multifactorial origin, resulting from 
a complex interaction of both intrinsic and extrinsic factors(Table 1).  
 
Extrinsic factors  Intrinsic factors
intermittent’’ sun exposure during childhood 
or teenage years 
Increasing age 
ingestion of arsenic acid (medicine, pesticides), Positive family history
ionizing radiation gender (male predominantly) 
X-ray and grenz-ray exposure Fitzpatrick skin type I-type2 
low vitamin intake Red or blond hair
high dietary energy, especially from fats light eye color (blue or green eyes)
topical nitrogen mustard administration immunosuppression
thermal burns 
Genodermatoses (albinism, xeroderma pigmentosa, 
Rasmussen syndrome, Rombo syndrome, Bazex–
Christol–Dupre syndrome, albinism and Darier’s disease, 
and the naevoid BCC syndrome (Gorlin’s syndrome)) 
Psoralen and UVA (PUVA) treatment posttransplantation
 scars, draining sinuses, ulcers, burn sites and 
foci of chronic inflammation
 
Table 1. Risk factors for basal cell carcinoma. 
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UV radiation (UVR), and especially UVB, is responsible for the majority of cutaneous 
damage and is believed to be the primary established risk factor in the development of BCC 
(9,10). The role of ‘‘intermittent’’ sun exposure during childhood or teenage years (periods 
that are supposed to be critical for tumor development) appears to be of particular 
importance and has been shown to be a strong risk factor for BCC. The infrequent, intense 
and intermittent sun exposure during childhood and adolescence, especially before the age 
of 20, increases the risk of BCC more than if a similar dose was delivered more continuously 
over the same time period (11). Increased risk of nodular, but not superficial BCC, has been 
reported in association with occupational sun exposure, Moreover, a strong association has 
been shown between BCC and skin lesions that are ‘‘objective’’ markers of cumulative sun 
exposure (whether long-term or intense intermittent), such as actinic keratoses and solar 
lentigines, which result from a combined effect of sun exposure and skin pigmentation 
characteristics (12, 13, 14). UVR especially prior to the age of 20 years is suggested to initiate 
a process of basal cell carcinogenesis (15). UVR has two major effects that influence BCC 
development, namely DNA damage and immunosuppression (16). Exposure to UVR, 
specifically UVB, induces covalent bonds in DNA between adjacent pyrimidines, generating 
photoproducts such as cyclodipyrimidine dimers (T ⁄T) and pyrimidine lesions which are 
mutagenic if not repaired. Unlike UVB, UVA may have more indirect effects in DNA 
through ROS (17). UVR is also a local immunosuppressant in skin, giving rise to the 
suggestion that this may compromise local antitumour activity. Exposure to UVR results in 
a cascade of events including a T-lymphocyte-mediated immunosupression (18). Burning 
and tanning response of skin (skin type) is important in determining BCC risk. BCCs are 
more common in males and those with skin types 1 and 2 demonstrate an increased 
susceptibility with relative risks between 4.0. and 2.1 (19, 20). 
In sporadic BCC, DNA repair capacity below the upper 30th percentile was associated with 
a 2-3-fold increase in BCC relative risk. However, some studies have reported increased 
repair in BCC patients and so batch variability and the effects of age, family history of skin 
cancer and current sun exposure may confound results (21). 
The incidence rates of BCC are increasing each year. These trends may be due to increases in 
both acute and prolonged sun exposure (due to altered life style and pro-tanning behavior), 
and the depletion of stratospheric ozone, together with the increasing aging of the general 
population (22). Similar to melanoma and in contrast to SCC, sporadic BCC may occur in 
individuals with intermittent extreme UV exposure behavior (11, 23). 
Other extrinsic risk factors, beyond UVR, predisposing to BCC, include ingestion of arsenic 
acid (medicine, pesticides), ionizing radiation, X-ray and grenz-ray exposure, low vitamin 
intake, high dietary energy, especially from fats, topical nitrogen mustard administration 
and thermal burns. Psoralen and UVA (PUVA) treatment, classically for psoriasis, carries a 
modest increased risk. Constitutional factors include gender, age, immunosuppression and 
genetic predisposition (a family history of BCC, genetically inherited nucleotide excision 
repair defects such as xeroderma pigmentosum) . Also, pigmentary traits, such as fair skin, 
blond or red hair, light eye color, tendency to sunburn and poor tanning ability (skin Type 
I), have all been associated with a higher risk of BCC (22-24). Fitzpatrick skin type I (always 
burns, never tans), male gender, red or blond hair and blue or green eyes have been shown 
to be associated with increased risk of BCC development. Several genodermatoses are 
associated with the development of BCC, including albinism, xeroderma pigmentosa, 
Rasmussen syndrome, Rombo syndrome, Bazex–Christol–Dupre syndrome, albinism and 
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Darier’s disease, and the naevoid BCC syndrome (Gorlin’s syndrome) (25). These 
syndromes variably either decrease epidermal pigmentation and thus increase the risk of 
UV light-induced oncogenic transformation or promote genotypic instability in the 
epidermis.(26) Nevoid BCC syndrome (NBCCS) is linked to chromosome 9q22, which 
harbours the PTCH gene where activating germline mutations have been found in  
BCC tissue (27, 28). Somatic PTCH mutation has also been described in sporadic BCC (29, 
30). Dysregulation of the PTCH pathway is thought to be a critical event in BCC 
development. The tumour suppressor gene (TSG) p53, involved in genome surveillance 
through the regulation of cell proliferation and death, is frequently inactivated in BCC 
(31, 32) with up to 56% of tumours displaying mutation in the conserved region of one 
p53 allele. Indeed, it has been suggested that p53 mutation is a crucial but late event in 
BCC progression (33). 
BCC may, like squamous cell carcinoma, arise in the setting of scars, draining sinuses, 
ulcers, burn sites and foci of chronic inflammation(15). The incidence of BCC arising from 
chronic wounds is low, and as few as 2.4% of malignancies develop from chronic leg 
ulcers(34). The role of immune compromise in provoking an increased risk of BCC may be 
due to impairment of the immune surveillance of oncogenic viruses. Immunosuppressive 
therapy also increases risk (ten-16 fold in renal transplant recipients) (35). BCC is the 
second most common cancer among solid organ transplant recipient(SOTR). The peak 
incidence rate was 5 years posttransplantation for patients older than 50 and 8 to 10 years 
for younger patients. Of the various organs transplanted, liver engraftment may bestow 
greater risk for BCC than others. BCCs in SOTR more often affected younger males and 
were more likely to present in sun-protected or bizarre locations, such as genitalia, 
external auditory meatus, and axilla. Lesions developed sooner after heart transplantation 
(5.7 years) than after renal transplantation (8.1 years). Renal transplant recipients with 
BCCs were more often younger and male compared to controls. Lesions were more 
commonly multifocal but not more likely to recur or metastasize. The mean time to tumor 
development was 10.5 years (36, 37). 
3. Clinicopathologic aspects of BCC 
The typical BCC is a pearly pink or flesh colored papule with telangiectasia. Lesions may be 
translucent or slightly erythematous with a rolled border, occasionally accompanied by 
bleeding, scaling or crusting(Fig. 1). Aggressive growth tumors tend to show more 
frequent ulceration and large, untended neoplasms can be locally destructive of eyes, ears 
and nares (38). BCCs are usually slow-growing tumors that only rarely metastasize (39). 
Growth of BCCs is usually localized to the area of origin; however, some BCCs tend to 
infiltrate tissues in a three-dimensional fashion through the irregular growth of finger-like 
projections, which may not be obvious on visual inspection (40, 41). If left untreated, or 
inadequately treated, the BCC can cause extensive tissue destruction, particularly on the 
face(Fig. 2). The clinical course of BCC is unpredictable; it may remain small for years, or 
it may grow rapidly or proceed by successive spurts of extension of tumor and partial 
regression (42). Thus, early prompt treatment is essential to minimize the morbidity of 
both cancer and treatment. Eighty percent of BCCs appear on the head and neck 
compared to 15% on the trunk and 5% on the extremities “larger lesions” are also more 
likely to be located in areas of the body other than the face where patients do not notice or 
complain about them as early (43). 
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A BCC can usually be diagnosed on the clinical aspect, but histological confirmation is 
necessary to determine the best treatment option. Although 26 histological subtypes have 
been described(44), BCC subtypes were categorized based upon the histologic classifications 
of Lang and Maize(45), Sexton and colleagues(46) and Kirkham(47): (1) those with 
nonaggressive growth patterns (superficial, nodular, and adnexal, such as follicular) or (2) 
those with aggressive growth patterns (keratinizing, micronodular, infiltrating, sclerosing, 
and perineural) or (3) both. 
The three most common tumor subtypes are nodular (nBCC), superficial (sBCC), and 
morpheaform. In a large, retrospective analysis of 13,457 cases of BCC diagnosed at a single 
center from 1967 to 1996, 79% of BCCs were nodular, 15% were superficial, and 6% were 
morpheaform In addition, nodular and morpheaform types were most commonly observed 
on the head region (90% and 95%, respectively), whereas 46% of superficial types were 
observed on the trunk region. (48) 
3.1 Nonaggresive BCC 
Nodular BCC is the most common variety and is usually composed of one or a few small, 
waxy, semitranslucent a flesh-to-pearl–colored papule with a characteristic rolled border 
that sometimes form around a central depression. Central ulceration and overlying 
telangiectases are also cardinal features(Fig. 3) (49). 
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Superficial BCC (sBCC) is often larger than other subtypes and occurs mainly on the trunk 
where they can be multiple. Superficial BCC may mimic psoriasis, fungus, or eczema. The 
superficial variant of BCC presents as an enlarging erythematous plaque with mild scale 
and a scalloped border(Fig. 4).  
 
 
 
 
Pigmented HNBCC are seen more commonly in darkskinned individuals and can mimic a 
mole or even a melanoma. BCCs may also demonstrate hyperpigmenation, leading to 
confusion with melanoma in some cases(Fig. 5). 
Cystic HNBCC are filled with fluid and may mimic benign cystic lesions, especially around 
the eye(50). 
3.2 Aggressive BCC 
This subgroup included BCCs with keratinizing, micronodular, infiltrating, sclerosing, and 
basosquamous carcinoma (51). 
A scar-like or morpheaform variant of BCC may appear as depressed, indurated plaque with 
ill-defined margins. 
BCCs with follicular pattern demonstrate basaloid nodular islands of tumor cells in 
association with a hair follicle; in addition, the tumor epithelium and surrounding stroma 
form structures reminiscent of follicular germs or contain horn cyst formation resembling a 
follicular structure or both. 
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Keratinizing BCCs show nodules of basaloid tumor cells which have a central foci of large 
horn cysts or pronounced squamous differentiation with keratinization or both; in addition 
to the undifferentiated basaloid tumor cells, parakeratotic tumor cells with elongated nuclei 
and slightly eosinophilic cytoplasm may also be present as strands, as concentric whorls, or 
as cells around the horn cysts. 
Basosquamous carcinoma is a subtype of BCC with aggressive behavior and higher tendency 
for recurrence and metastases. Most authors recognize that basosquamous carcinoma has a 
nonspecific clinical presentation and the diagnosis is made only after biopsy. The majority of 
lesions arise on the head and neck (80%) with the central face and perinasal areas being the 
most common locations (30%). The location of tumors is similar to other types of BCC. The 
term ‘‘basosquamous carcinoma’’ usually implies a BCC with areas of lineage differentiation 
into squamous cell carcinoma (52). This tumor has areas of BCC and squamous cell 
carcinoma plus a transition zone between them. The reported incidence of basosquamous 
carcinoma ranges from 1.2% to 2.7%. Published recurrence rates are 12% to 51% for surgical 
excision and 4% for Mohs micrographic surgery. The incidence of metastasis is at least 5%. 
The aggressive biological behavior and clinical course distinguish basosquamous carcinoma 
from other forms of BCC. Pulmonary metastases occurred in 7.4% of basosquamous 
carcinomas compared with 0.87% of squamous cell carcinomas. The incidence of perineural 
invasion was 7.9%. There are no clinical features to distinguish basosquamous carcinoma 
and the diagnosis is made only after biopsy. It presents in the same locations and with 
similar clinical characteristics as other BCCs (53). 
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3.3 BCC with mixed histology 
BCC with mixed histology (BCC-MH) is a cutaneous neoplasm which demonstrates two or 
more pathologic patterns of tumor within the same malignancy, such as superficial BCC in 
the papillary dermis and sclerosing BCC in the deeper reticular dermis (1–6). The incidence 
of BCCs with mixed histology is varied between 11% and 43% (54). BCC with mixed 
histology is most commonly found on the nose, followed by the ear, cheek, and scalp. This is 
not surprising as the most frequently reported site for either primary or recurrent BCCs is 
the nose (55, 56). BCCs with mixed histology (almost 40%) should be treated according to 
their most aggressive histopathological subtype. Shave/punch biopsy specimens fail to 
diagnose one of both subtypes in approximately 20% of cases (1). 
The different histomorphologic subgroups have their specific clinical correlates. On rare 
occasions, a lesion manifests tenderness or pain which can be a clue to perineural infiltration 
in the aggressive growth varieties. Sensorimotor compromise has been reported particularly 
in lesions of the preauricular and cheek areas (57). Tumor aggressiveness seems to correlate 
with the presence of perineural invasion that has an incidence of 1% in BCC. Perineural 
spread is a well-documented feature of cutaneous tumors and may portend a more 
aggressive course: perineural invasion is associated with larger, more aggressive tumors, 
and the risk of 5-year recurrence is higher (58). The choice and the selection of the most 
appropriate therapy depend on many factors, including the size of the tumor, location, 
whether the tumor is primary or recurrent, histology, and individual patient factors. 
Documentation of the specific anatomical location, size in millimeters, and appearance of 
the cutaneous neoplasm is helpful, as it may be required for later staging. Appearance 
includes such characteristics as color, margins, symmetry, diameter, and the presence of 
ulceration. Such features include size greater than 2 cm, location on the central face or ears, 
long duration, perineural or perivascular invasion, and poorly defined margins. 
Histologically, morpheaform, metatypical, and infiltrative growth patterns associate with 
poorer clinical outcomes (59). The ABCD (asymmetry, border, color, and diameter) 
mnemonic used in melanoma is helpful here too. Many surgeons find photographic 
documentation of lesions an accurate and speedy means of mapping lesions. Metastatic 
spread of BCC is very rare, but it is not impossible. Accordingly, palpation of the regional 
lymph nodes is indeed a mandatory part of the complete workup (60, 61). 
4. Metastatic disease 
BCCs very rarely metastasize, occurring in 0.0025% to 0.55% of cases (62). Metastatic BCC 
generally tends to occur on a background of large neglected tumors on the head and neck, 
mainly in men Metastases most are said to more closely correlate to the size and depth and 
less so to the histologic subtype of the original tumor. The incidence of metastases and/or 
death is said to correlate to large tumors greater than 3 cm in diameter in which setting 
patients are said to have a 1–2% risk of metastases that increases to up to 20–25% in lesions 
greater than 5 cm and up to 50% in lesions greater than 10cm in diameter. A ‘giant’ BCC is 
designated as one that is greater than 5 cm in diameter and has a significant risk of 
morbidity and mortality. A BCC arising in a young person (ie less than 35 years of age) may 
have an aggressive clinical course (63, 64). 
When metastatic spread occurs, regional lymph nodes are affected first followed by bone, 
lung, liver and abdominal viscera.. An BCC that metastasizes has an extremely poor 
prognosis;, the median survival of patients with metastatic BCC is about 10 months. There is 
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less than 20% survival at 1 year and approximately 10% survival at 5 years (65). 
Occasionally surgical resection of metastatic disease is possible; cases should be referred to 
specialist centers for full assessment (66). 
5. Other malignancies 
The risk of developing a squamous cell carcinoma is increased slightly after developing a 
BCC (6% risk at 3 years) and there is also a higher risk of developing a malignant melanoma. 
The relationship of development of other malignancy after development of a BCC is 
uncertain – some studies have shown a small increased risk with cancer of the lung, thyroid, 
mouth, breast and cervix and non-Hodgkin’s lymphoma, whilst others have shown no 
association (67). 
6. Treatment 
The choice for a treatment modality should depend on the site, the size and whether the 
BCC shows indolent (superficial or nodular BCC) or aggressive growth (infiltrative BCC or 
basosquamous carcinoma) (5, 8). Careful selection is essential and depends upon individual 
factors. A biopsy of the lesion prior to definitive treatment can help guide choice. 
Essentially, the method chosen should take into account the prognostic factors for the 
tumour under consideration, local facilities available, operator expertise and any 
comorbidity. Several different modalities are used in the treatment of BCC (1, 50) (Table 2). 
 
Anatomical location  central face or ears 
Tumour size  greater than 2 cm 
Histological type  morpheaform, metatypical, and infiltrative 
Perineural/ perivascular invasion portend a more aggressive course 
Recurrence scar tissue can cover residual tumour,  
Treatment failure  
A decrease in resection margin increases the 
recurrence rate. The optimal resection margin in 
terms of recurrence is 5 mm 
Immunocompromised patients  
more aggressive biologic behavior, higher 
recurrence rate 
Table 2. Prognostic factors for BCC  
 
Invasive Non -invasive 
Excision Photodynamic therapy 
Mohs’ micrographic surgery Radiotherapy 
Curettage and cautery Chemotherapy : 5-fluorouracil  imiquimod 
Cryosurgery  
Table 3. Treatment options for basal cell carcinoma. 
7. Surgery 
This method requires that normal tissue surrounding the tumor margins be removed in 
addition to diseased tissue to ensure that the tumor has been fully excised. BCC lesions are 
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resected with a preplanned size of surgical margin depending on the surgeon preference, 
the location, and the size of the lesion. The goal is to safely predict appropriate margins of 
resection of BCC lesions while sacrificing a minimum amount of healthy surrounding skin. 
Although surgical excision is a common method for treating BCC, there are important safety 
and quality of life, Patient age and health status (e.g. immunocompromized) may increase 
associated risks with a surgical procedure including bleeding and infection. In addition, 
some patients are afraid of surgery, particularly when treating larger. 
An advantage of surgical treatments is the histological examination of tumor margins to 
establish clearance. One disadvantage of surgical excision is incomplete margin control. The 
incidence of incomplete excision of BCC has varied, with reports ranging from 4.7% to 
10.8% of treated patients (68, 69). The success of surgical excision can vary depending on the 
experience of the surgeon, histologic subtype, and excision margin (70). In a retrospective 
cohort analysis of 1983 BCC cases, significant risk factors for incomplete excision included 
lesions located on the head and neck ( P < 0.001), surgeons performing < 51 procedures 
during the 2- year study period ( P < 0.001), and patients with aggressive histologic BCC 
subtypes (e.g. morpheaform and infiltrative) ( P < 0.01). The study further indicated that 
curettage before surgical excision of BCC decreased the incomplete excision rate by up to 
24% ( P = 0.03) (71). 
A decrease in resection margin increases the recurrence rate. Relative risk of recurrence 
increases steadily. The relative risks (hazard ratio) for 4-, 3-, and 2-mm margins are 4.2, 6.5, 
and 10, respectively. It is clear that smaller margins are inherently riskier than larger ones, 
even if the difference is 1 mm. the reported mean recurrence rates decrease linearly with 
increasing size of margins until it reaches 5 mm. The optimal resection margin in terms of 
recurrence is 5 mm.(72) 
Consistently, relative risk is inversely proportional to the size of the surgical margin. Using 
this criterion alone, the best margin in terms of relative recurrence is a 5-mm margin. 
However, the anatomical constraints require prejudice in choosing the resection margins, 
especially for lesions of the face. Thus, for those surgeons who desire a minimum 95 percent 
cure rate, these data indicate that a 3-mm surgical margin can be safely used for BCC lesions 
2 cm or smaller. Furthermore, a positive pathologic margin has a mean recurrence rate of 27 
percent and thus does not necessarily indicate that a BCC will recur. Thus, when faced with 
a positive surgical margin, a case-by-case consideration of the risks of observation versus 
reresection should be applied when determining the next step in management (72). 
A study using MMS for excising primary (ie previously untreated BCC) found that for small 
(<20 mm) well defined tumours 3 mm surgical margins gave tumour clearance rates of 85%, 
whereas 4–5 mm margins gave clearance rates of 95%. Large and morphoeic BCCs require 
wider margins to achieve complete histological resection (13–15 mm surgical margins for 
95% clearance) (73). 
7.1 Mohs micrographic surgery 
Mohs micrographic surgery (MMS) is a specialized surgical procedure that is commonly 
used for patients who present with large (> 2 cm) tumors, high-risk morphea-type BCC 
tumors, recurrent tumors, or tumors located in cosmetically sensitive locations such as the 
face (74). But Mohs’ micrographic surgery (MMS) is a specialised technique that uses 
horizontal frozen sectioning to examine serial sections of tissue until all margins are free of 
tumour. MMS allows for greater tissue conservation and margin control compared with 
other surgical procedures. This technique histologically maps the margins of the tumor to 
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more accurately delineate the pattern of tumor infiltration into tissue, while sparing healthy 
tissue. MMS gives high cure rates for tumours in high-risk sites with maximal conservation 
of uninvolved tissue. The suggested overall 5-year cure rates for primary and recurrent BCC 
are 99% and 94.4%, respectively (75, 76). 
7.2 Curettage and electrodesiccation 
Electrodesiccation and curettage (ED & C) is the most common method used by 
dermatologists to treat primary nBCC and sBCC tumors < 1.5 cm in diameter. After the 
tumor is scraped with a curette, the area is then treated with electrosurgery 
(electrodesiccation or coagulation) to control bleeding and eradicate cancer cells remaining 
around the wound margins and circumference. Typically two or three treatment cycles are 
recommended to completely remove the tumor (77). Recurrence rates are varied between 3% 
to 19%im 5 years (78). Recurrence was higher in nasal, paranasal, and forehead areas (78). 
Although ED & C appears to have a higher risk for disease recurrence compared with 
surgical excision, a nonrandomized retrospective chart review suggested that the two 
treatment modalities are not significantly different (79). If the dermis and the fatty layer is 
penetrated with ED & C, surgical excision should be performed.Although multiple cycles of 
ED & C are recommended, there have been reports that single-cycle therapy may reduce the 
risk of scarri(74). However, a reduction in ED & C treatment cycles may lead to higher 
recurrence rates. 32(80) Atrophic or hypertropic scar can be develop after ED & C (78). 
Problematic wounds, with subsequent poor cosmesis, are occasional sequelae. 
7.3 Cryosurgery 
Cryosurgery is a cytodestructive technique that involves using a liquid nitrogen spray or 
probe to induce cell necrosis by exposing tissue to low temperatures. Cryosurgery is 
commonly reserved for tumors with welldefine borders, and two freeze–thaw cycles with a 
tissue temperature of - 50 °C are recommended. 6. (74) two freeze–thaw cycles of 30 s each 
are still recommended in the treatment of facial BCC. A systematic review of recurrence 
rates of studies ( ≥ 50 patients) published between 1970 and 1997 indicated that cryotherapy 
in the treatment of primary BCC resulted in a cumulative 5-year recurrence rate of 4% to 
17%(81). For treatment of recurrent BCC, the recurrence rate has ranged from 4% (for 56 
tumors) to 12% (for 164 tumors), with variable follow-up periods reported (82, 83). 
Cryosurgery is associated with many adverse events. Shortterm adverse events include 
perioperative and postoperative pain, tenderness, bulla or vesicle formation, erythema, 
sloughing of necrotic tissue or eschar formation, and localized edema (84). This procedure 
can also result in scarring including hypertrophic scarring, local hypopigmentation, and/or 
peripheral hyperpigmentation (84). When aggressive cryosurgery is used, tumor recurrence 
may become extensive before diagnosis because of the tumor’s concealment by a fibrous 
scar (74). Cryosurgery should be avoided in areas of hair growth (e.g. scalp or beard area) 
and in patients with conditions sensitive to temperature, including Raynaud’s syndrome, 
cold panniculitis, and cryoglobulinemia. 
8. Photodynamic therapy 
Photodynamic therapy (PDT), which uses the intrinsic cellular haem biosynthetic pathway 
and photo illumination to initiate tumour cell destruction, is a relatively new treatment for 
superficial BCCs, which is increasingly available for superficial non-melanoma skin cancers. 
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After topical application, precursor molecules are selectively concentrated in tumour tissue 
where they undergo further metabolism. After irradiation by visible light of a certain 
wavelength, these molecules become excited and jump to a higher energy level. Upon 
release of this energy, reactive oxygen species are released; these cause cellular destruction, 
and so resolution of the tumour – without scarring. (It is thought that, fundamentally, holes 
are punched into cellular organelles, especially mitochondria, so the cells can no longer 
function.). This procedure causes cell death in two ways: through cellular damage and 
apoptosis. Several studies have indicated that sBCC lesions do not clear with single-
treatment PDT The best clearance rate (96% median follow up, 27 months).) is achieved with 
two exposures 1 week apart. PDT offers patients with large and/or multiple superficial 
BCCs particular benefits as it gives a low rate of adverse events with good cosmetic results 
by selectively targeting tumour cells (3). 
Although one advantage of PDT is that multiple BCC tumors can be treated simultaneously, 
PDT is a relatively inconvenient treatment option. Treatment involves a two stage process 
requiring several office visits. After the topical agent is applied, patients must wait several 
hours before the light-application phase of the treatment can be initiated. This second-stage 
of treatment must be performed within a certain time frame after agent application. 
Furthermore, because single PDT treatments demonstrate poor efficacy in BCC, multiple 
visits to a healthcare provider’s office are required. Increased photosensitivity during the 
first-stage of treatment provides additional inconvenience because patients must avoid 
sunlight and bright indoor lighting to reduce the risk of stinging and/or burning sensations 
from photosensitized skin. Treatment with PDT is typically associated with localized 
adverse events, including stinging or burning, erythema, and edema (85). Photosensitivity is 
also associated with this treatment regimen. After application of topical agents, patients 
should avoid exposure to sunlight or bright indoor light until after controlled exposure to 
the light source that completes treatment. Treatment with PDT is contraindicated in patients 
with porphyria, known allergies to porphyrins, and patients with photosensitivity to wave 
lengths of applied light sources. Further development of PDT for BCC will likely make this a 
more practical and useful modality (86). 
9. Radiotherapy 
Radiotherapy is an effective treatment for many BCCs. It has been particularly useful in the 
treatment of elderly patients and for larger tumors or tumors in difficult-to treat locations. 
Lower risk areas, such as the trunk and extremities, as well as the genitalia, hands, and feet 
are usually not treated with this modality. Radiation therapy may be a very useful modality 
as adjunct treatment for BCC when margins are positive after excision and for extensive 
perineural or large nerve involvement. The total dose and treatment regimen (e.g. number 
of fractionated doses) depends on many factors including tumor location, size, type, and 
depth. A study of BCC irradiated by a ‘standardized’ X-ray therapy schedule indicated an 
overall 5-year recurrence rate of 7.4% for primary ( n = 862) and 9.5% for recurrent ( n = 211) 
BCC. Radiation therapy is not recommended in younger patients (e.g. < 50 years of age) as 
less favorable cosmetic outcomes (e.g. late-onset changes of cutaneous atrophy and 
telangiectasia) may result over time, and there is a risk of developing additional 
nonmelanoma skin cancers in the radiation field (usually after 10–20 years) (87). Radiation 
therapy is contraindicated in certain genetic disorders, which predisposes patients to skin 
cancers (e.g. patients with Gorlin’s syndrome, xeroderma pigmentosum, or connective tissue 
diseases, such as lupus and scleroderma)(88). 
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10. Chemotherapy of BCC  
10.1 Topical 5-Fluorouracil 
Topical 5-fluorouracil cream is useful for low-risk tumours on the trunk and limbs, but there 
is a high incidence of local side effects. 5-Fluorouracil (5-FU) is a chemical ablative agent that 
inhibits DNA synthesis, prevents cell proliferation, and causes tumor necrosis. Solution and 
cream formulations of 5% 5- FU administered twice daily for at least 6 weeks have been 
approved by the FDA in the treatment of sBCC when conventional methods are impractical 
(e.g. difficult treatment site). 47However, therapy may be required for as long as 10–12 
weeks. Because limited data are available, the actual clearance rate for the topical treatment 
of sBCC with 5-FU is currently unknown. Application of 5-FU causes severe local skin 
reactions, including pain and burning, pruritus, irritation, inflammation, swelling, 
tenderness, hyperpigmentation, and scarring. (48)  
10.2 Imiquimod 
Imiquimod is a member of a newer class of agents called immune-response modifiers. 
Imiquimod is currently approved by the FDA in the treatment of external genital and 
perianal warts and actinic keratosis on the face or scalp. The mechanism of action of 
imiquimod is thought to occur through the activation of macrophages and other cells via 
binding to cellsurface receptors, such as Toll-like receptor (89). This binding activity induces 
proinflammatory cytokine secretion (e.g.interferon- α and tumor necrosis factor-α ) favoring 
a type 1 helper T-cell-mediated immune response because of the generation of cytotoxic 
effector cells Investigators noted a significant correlation between the histologic clearance 
rate and severity of local skin reactions (i.e. erythema, erosion, and scabbing/crusting) 
commonly experienced during treatment with imiquimod 5% cream. The data suggested 
that as the severity of these three local skin reactions increased, there was a greater trend in 
histologic clearance of sBCC (48). 
In addition to sBCC, imiquimod also has demonstrated efficacy in the treatment of 
nBCC.50,56 (90, 91) Treatment with imiquimod once daily, seven times per week, for either 
6 or 12 weeks resulted in nBCC histologic clearance rates of 71% to 76% (90). 
Because imiquimod promotes an inflammatory reaction to treat the tumor, treatment is 
generally associated with mild to- moderate local skin reactions, with severity related to 
frequency of application (92, 93). In a phase II study, the most common local skin reactions 
were erythema, crusting, flaking, and erosion (92). However, these dose-related side-effects 
were generally well tolerated, and none of the patients discontinued because of local skin 
reactions. 
In addition to monotherapy, imiquimod 5% cream may also be useful as adjunctive therapy 
in the treatment of BCC. Treatment with imiquimod significantly reduced the size of the 
target tumor and thereby resulted in a smaller cosmetic defect from the MMS excision 
compared with vehicle. Adjunctive therapy with imiquimod reduced the frequency of 
residual tumor with ED & C compared with ED & C alone and also appeared to improve 
cosmetic appearance. These studies suggest that imiquimod 5% cream may be useful as 
adjunctive therapy in the treatment of nBCC (48). 
11. Issues in the treatment of BCC 
BCC treatments have many advantages and disadvantages, which depend on many factors, 
including tumor type, tumor location, cosmetic considerations, and physician and patient 
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convenience. Surgical procedures such as MMS and surgical excision have the lowest 5-year 
recurrence rates (Table 4). However, effective clearance of BCC tumors with surgical 
procedures is highly dependent on tumor margins and the skill of the healthcare provider. 
Thissen et al. (81) recommend that surgical excision is preferred over common procedures 
such as cryosurgery and ED & C, provided surgery is not contraindicated. With PDT, there 
is limited tissue penetration (i.e. depth), a critical requirement when treating invasive 
tumors. Mohs micrographic surgery is recommended for larger BCC tumors in high-risk 
areas of the face and head and for tumors with aggressive growth patterns (81). 
 
 
Treatment option  Description 5-year recurrence rate, % 
Surgical excision  
Surgical excision of diseased and 
surrounding healthy tissue 
Complete excision: 3–14 
Incomplete excision: 26–42 
Curettage and 
electrodesiccation  
Multiple cycles of diseased tissue 
excision and electrodesiccation to 
control bleeding and eradicate cancer 
cells in surrounding margins 
3–19 
Mohs micrographic 
surgery  
Specialized surgical procedure to 
maximize excision of diseased tissue 
and minimize loss of healthy tissue 
Primary BCC: 1 
Recurrent BCC: 6–10 
Cryosurgery  
Multiple cycles of cytodestruction  
(i.e. cell necrosis) of diseased tissue 
with liquid nitrogen 
4–17 
Radiation  
X-rays or high-energy particles 
administered in fractionated doses to 
kill tumor cells 
7–10 
PDT  
Multiple cycles of 2-stage process 
(photosensitization via topical agent 
and light exposure) creates cytotoxic 
reaction in tumor cell 
Single cycle: 21–50* 
Double cycle: 4† 
BCC = basal cell carcinoma; PDT = photodynamic therapy; ALA = aminolevulinic acid.  
* Projected overall cure rate based on median follow up of 19–35 months.  
† Study of 26 lesions with median follow up of 27 months. Data and table from 48th reference. 
Table 4. Treatment options and recurrence rates of BCC  
12. Recurrency of BCC  
The likelihood of BCC recurrence may be influenced by one or more factors(Table 2). In 
addition to fthe tumor’s treatment, the cancer’s biologic behavior and the patient’s immune 
status are related to the incidence of tumor recurrence. For example, in immunosuppressed 
individuals, BCCs not only demonstrate more aggressive biologic behavior but also have a 
significantly higher recurrence rate as compared with this malignancy in patients who have 
an intact immune system (94). 
The histologic subtype of BCC influences the biologic behavior of the tumor. Recurrent 
BCCs are commonly associated with a primary cancer that has an aggressive histologic 
subtype (95-98). 
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Also, BCCs with aggressive histologic patterns require more aggressive treatment; in 
addition, when the Mohs micrographic surgical technique is used, a greater number of 
stages are required to achieve tumor free margins as compared with BCCs without 
aggressive tumor growth patterns (99). 
Inadequate treatment of BCCMH may represent an unsuspected etiology for recurrent skin 
cancer. For example, an unexpected aggressive pathologic pattern of BCC may not be 
detected after a superficial biopsy. Subsequently, the cancer may recur if the initial 
treatment for the diagnosed nonaggressive tumor subtype is inadequate for the 
undiscovered aggressive carcinoma. Clinical recurrence of cancer results when there has 
been persistence of the original tumor secondary to inadequate eradication (54). The 
recurrence rate for BCC lesions with positive margins calculated from the aggregated data is 
27 percent (72). The reported percent of BCC recurrence varies depending on the treatment 
modality (54). 
Recurrent BCC (rBCC) is known to be a high-risk tumour with a worse prognosis than 
primary BCC (50, 59, 76, 100). This may be due to the fact that scar tissue can cover residual 
tumour fields or because the appearance of basaloid tumour cells in recurrent tumours is 
frequently squamified, lacy and morpheaform, which may be easily missed in scar tissue 
(76). The only RCT investigating treatment modalities in rBCC showed that after 5 years of 
follow-up MMS is the preferred treatment for facial rBCC because of statistically significant 
lower recurrence rates (101). 
Besides tumour characteristics, patient characteristics are of importance when choosing a 
treatment for an individual. In a few cases where surgery is impossible or undesirable, it 
may be advantageous to treat a patient with a different, possibly less effective, treatment. 
Particular management difficulties are posed by recurrent tumours. In general, they are best 
treated by Mohs’ micrographic surgery in high-risk sites and excision elsewhere. 
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